Walter Reed Brings Revolutionary CAR-T Cancer Therapy to Troops

Cancer patients at Walter Reed just gained access to one of medicine's most promising breakthroughs, a therapy that turns their own cells into cancer-fighting machines.

The Murtha Cancer Center at Walter Reed National Military Medical Center in Bethesda, Maryland recently received approval to deliver CAR-T therapy. This advanced treatment helps patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia by engineering their blood cells to seek out and destroy cancer.

Here's how it works. Doctors extract T-cells from a patient's blood and send them to a laboratory for genetic modification. Scientists add special receptors that teach these cells to recognize and attack specific cancer cells. After a brief round of low-dose chemotherapy to prepare the body, the supercharged cells return to the patient's bloodstream and get to work.

The game-changing part? Patients only need one infusion. "When it's done, it's done," said Army Major Dr. Arjun Kalra, a staff physician at Walter Reed. "Patients who respond positively won't need anything else, no other cancer-directed therapies."

Before CAR-T, patients whose cancer returned or didn't respond to initial treatment faced limited options. Stem cell transplants only worked for patients in excellent overall health. Many ran out of choices.

Navy Commander Dr. Daniel Bowers championed bringing CAR-T to Walter Reed after following its development since 2014. The FDA approved the therapy in 2017, but logistical challenges mean only select facilities can offer it. Walter Reed is now the sole military hospital with this capability.

The therapy proves especially valuable for lymphoma patients, which Bowers notes are among the curable cancers doctors treat. Active-duty service members can receive treatment and return to unrestricted duties, making it particularly relevant for military medicine.

The Ripple Effect

Walter Reed's CAR-T program opens doors beyond current treatments. The capability positions the cancer center to participate in clinical trials for new CAR-T products targeting different cancers. Military families who previously had no access to this therapy, or had to seek treatment at civilian facilities, can now receive cutting-edge care within the military healthcare system.

The program reflects founder Dr. Carl June's Navy roots. June, a retired Navy captain, completed his residency at what's now Walter Reed and led immunology research at the Naval Medical Research Institute before pioneering CAR-T at the University of Pennsylvania.

Patients face careful screening before treatment. The team evaluates those with advanced lymphomas that haven't responded to chemotherapy, ensuring they don't have disqualifying heart or lung problems. Once cleared, patients follow a preparation regimen before their single infusion.

For many patients, CAR-T represents their last hope. Bowers is excited to see how the therapy brings optimism to those losing faith in recovery. "This has been one of the biggest innovations in bloodborne cancer therapy in the last 15 years," he said.

Walter Reed's commitment to staying on the cutting edge means service members and their families can access tomorrow's medicine today.